1
|
Iurlo A, Cattaneo D, Consonni D, Castagnetti F, Miggiano MC, Binotto G, Bonifacio M, Rege-Cambrin G, Tiribelli M, Lunghi F, Gozzini A, Pregno P, Abruzzese E, Capodanno I, Bucelli C, Pizzuti M, Artuso S, Iezza M, Scalzulli E, La Barba G, Maggi A, Russo S, Elena C, Scortechini AR, Tafuri A, Latagliata R, Caocci G, Bocchia M, Galimberti S, Luciano L, Fava C, Foà R, Saglio G, Rosti G, Breccia M. Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study. Front Pharmacol 2023; 14:1154377. [PMID: 37033642 PMCID: PMC10076530 DOI: 10.3389/fphar.2023.1154377] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Accepted: 03/14/2023] [Indexed: 04/11/2023] Open
Abstract
TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevant morbidity and mortality. Consequently, TKIs dose reduction is often used to prevent AEs. However, data on its impact on successful treatment-free remission (TFR) are quite scarce. We conducted a retrospective study on the outcome of CML subjects who discontinued low-dose TKIs from 54 Italian hematology centers participating in the Campus CML network. Overall, 1.785 of 5.108 (35.0%) regularly followed CML patients were treated with low-dose TKIs, more frequently due to relevant comorbidities or AEs (1.288, 72.2%). TFR was attempted in 248 (13.9%) subjects, all but three while in deep molecular response (DMR). After a median follow-up of 24.9 months, 172 (69.4%) patients were still in TFR. TFR outcome was not influenced by gender, Sokal/ELTS risk scores, prior interferon, number and last type of TKI used prior to treatment cessation, DMR degree, reason for dose reduction or median TKIs duration. Conversely, TFR probability was significantly better in the absence of resistance to any prior TKI. In addition, patients with a longer DMR duration before TKI discontinuation (i.e., >6.8 years) and those with an e14a2 BCR::ABL1 transcript type showed a trend towards prolonged TFR. It should also be emphasized that only 30.6% of our cases suffered from molecular relapse, less than reported during full-dose TKI treatment. The use of low-dose TKIs does not appear to affect the likelihood of achieving a DMR and thus trying a treatment withdrawal, but might even promote the TFR rate.
Collapse
Affiliation(s)
- A. Iurlo
- Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
- *Correspondence: A. Iurlo,
| | - D. Cattaneo
- Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - D. Consonni
- Epidemiology Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - F. Castagnetti
- Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. and A. Seràgnoli”, University of Bologna, “S. Orsola-Malpighi” Hospital, Bologna, Italy
| | - M. C. Miggiano
- Division of Hematology, San Bortolo Hospital, Vicenza, Italy
| | - G. Binotto
- Department of Medicine, Hematology and Clinical Immunology, Padua School of Medicine, Padua, Italy
| | - M. Bonifacio
- Department of Medicine, Section of Hematology, University of Verona, Verona, Italy
| | - G. Rege-Cambrin
- Division of Internal Medicine and Hematology, San Luigi Gonzaga Hospital, Turin, Italy
| | - M. Tiribelli
- Division of Hematology and BMT—Udine Hopsital, ASUFC and Department of Medicine—University of Udine, Udine, Italy
| | - F. Lunghi
- Division of Hematology and BMT, IRCCS San Raffaele Hospital, Milan, Italy
| | - A. Gozzini
- Division of Hematology, AOU Careggi, Firenze, Italy
| | - P. Pregno
- Division of Hematology, AOU Città della Salute e della Scienza, Torino, Italy
| | - E. Abruzzese
- Hematology Division, Sant’Eugenio Hospital, Rome, Italy
| | - I. Capodanno
- Division of Hematology, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
| | - C. Bucelli
- Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - M. Pizzuti
- Hematology Unit, Ospedale Potenza, Potenza, Italy
| | - S. Artuso
- Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - M. Iezza
- Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. and A. Seràgnoli”, University of Bologna, “S. Orsola-Malpighi” Hospital, Bologna, Italy
| | - E. Scalzulli
- Division of Hematology, Department of Precision and Translational, Policlinico Umberto 1, Sapienza University, Rome, Italy
| | - G. La Barba
- Hematology Unit, Azienda USL di Pescara, Pescara, Italy
| | - A. Maggi
- Division of Hematology, Hospital “S. G. Moscati”, Taranto, Italy
| | - S. Russo
- Division of Hematology, Dipartimento di Patologia Umana dell''Adulto e dell'Età Evolutiva, Policlinico G. Martino, University of Messina, Messina, Italy
| | - C. Elena
- UOC Ematologia 1, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - A. R. Scortechini
- Division of Hematology, Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - A. Tafuri
- Division of Hematology, Azienda Ospedaliera Universitaria Sant'Andrea, Rome, Italy
| | - R. Latagliata
- Division of Hematology, Belcolle Hospital, Viterbo, Italy
| | - G. Caocci
- Department of Medical Sciences and Public Health, University of Cagliari, Businco Hospital, Cagliari, Italy
| | - M. Bocchia
- Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy
| | - S. Galimberti
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - L. Luciano
- Division of Hematology, Department of Clinical Medicine and Surgery, Federico II University, Napoli, Italy
| | - C. Fava
- Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
| | - R. Foà
- Division of Hematology, Department of Precision and Translational, Policlinico Umberto 1, Sapienza University, Rome, Italy
| | - G. Saglio
- Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
| | - G. Rosti
- Scientific Direction, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - M. Breccia
- Division of Hematology, Department of Precision and Translational, Policlinico Umberto 1, Sapienza University, Rome, Italy
| |
Collapse
|
2
|
Moia R, Favini C, Talotta D, Sagiraju S, Bruna R, Dondolin R, Della Starza I, Soscia R, Andorno A, Mercalli F, Deambrogi C, Rasi S, Petrucci L, Bellissimo T, Luciano Boldorini R, Di Rocco A, Del Giudice I, Martelli M, Foà R, Gaidano G. P1281: LIQUID BIOPSY PROVIDES COMPLEMENTARY INFORMATION TO TISSUE BIOPSIES FOR THE MOLECULAR CLASSIFICATION OF DLBCL PATIENTS. Hemasphere 2022. [PMCID: PMC9431283 DOI: 10.1097/01.hs9.0000847988.92666.b7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
3
|
Buske C, Dreyling M, Alvarez-Larrán A, Apperley J, Arcaini L, Besson C, Bullinger L, Corradini P, Giovanni Della Porta M, Dimopoulos M, D'Sa S, Eich HT, Foà R, Ghia P, da Silva MG, Gribben J, Hajek R, Harrison C, Heuser M, Kiesewetter B, Kiladjian JJ, Kröger N, Moreau P, Passweg JR, Peyvandi F, Rea D, Ribera JM, Robak T, San-Miguel JF, Santini V, Sanz G, Sonneveld P, von Lilienfeld-Toal M, Wendtner C, Pentheroudakis G, Passamonti F. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open 2022; 7:100403. [PMID: 35272130 PMCID: PMC8795783 DOI: 10.1016/j.esmoop.2022.100403] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2021] [Revised: 01/13/2022] [Accepted: 01/18/2022] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. METHODS This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. RESULTS AND CONCLUSION The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.
Collapse
Affiliation(s)
- C Buske
- Institute of Experimental Cancer Research, Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
| | - M Dreyling
- Department of Medicine III at LMU Hospital, Munich, Germany
| | - A Alvarez-Larrán
- Hematology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - J Apperley
- Centre for Haematology, Imperial College London, Hammersmith Hospital, London, UK
| | - L Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - C Besson
- Service d'Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France; UVSQ, Inserm, CESP, Villejuif, France
| | - L Bullinger
- Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Germany; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - P Corradini
- Hematology Division, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - M Giovanni Della Porta
- Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
| | - M Dimopoulos
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - S D'Sa
- UCLH Centre for Waldenström and Neurohaematology, University College London Hospitals NHS Foundation Trust, London, UK
| | - H T Eich
- Department of Radiation Oncology, University of Muenster, Münster, Germany
| | - R Foà
- Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - P Ghia
- Strategic Research Program on Chronic Lymphocytic Leukemia and Laboratory of B Cell Neoplasia, Division of Molecular Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
| | - M G da Silva
- Department Of Hematology, Portuguese Institute of Oncology, Lisbon, Portugal
| | - J Gribben
- Barts Cancer Institute, Queen Mary University of London, London, UK
| | - R Hajek
- Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
| | - C Harrison
- Clinical Director - Haematology, Haemostasis, Palliative Care, Cellular Pathology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - M Heuser
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany
| | - B Kiesewetter
- Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
| | - J J Kiladjian
- Université de Paris, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, Paris, France
| | - N Kröger
- Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - P Moreau
- Hematology Department, University Hospital Hotel-Dieu, Nantes, France
| | - J R Passweg
- Hematology Division, Basel University Hospital, Basel, Switzerland
| | - F Peyvandi
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
| | - D Rea
- University Medical Department of Hematology and Immunology, France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Hôpital Saint-Louis, Paris, France
| | - J-M Ribera
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - T Robak
- Department of Hematology, Medical University of Lodz, Lodz, Poland
| | - J F San-Miguel
- Clínica Universidad de Navarra (CUN), Centro de Investigación Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBERONC, Pamplona, Spain
| | - V Santini
- MDS Unit, Hematology, DMSC, AOUC, University of Florence, Florence, Italy
| | - G Sanz
- Hematology Department, Hospital Univesitario y Politecnico La Fe, Valencia; CIBERONC, IS Carlos III, Madrid, Spain
| | - P Sonneveld
- Erasmus MC Cancer Institute, Department of Haematology, Rotterdam, The Netherlands
| | - M von Lilienfeld-Toal
- Department of Hematology and Medical Oncology, University Hospital Jena, Jena, Germany; Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute, Jena, Germany
| | - C Wendtner
- Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University, Munich, Germany
| | - G Pentheroudakis
- Scientific and Medical Division, European Society for Medical Oncology, Lugano, Switzerland
| | - F Passamonti
- Department of Medicine and Surgery, University of Insubria, Varese, Italy.
| |
Collapse
|
4
|
Rostagno E, Campanati A, Mordini N, Cannici C, Cioce M, De Cecco V, Samarani E, Foà R, Olivieri A, Botti S. Phototherapy and topical treatments for cutaneous graft versus host disease in hematopoietic stem cell transplantation patients: A scoping review. J Eur Acad Dermatol Venereol 2022; 36:1003-1015. [DOI: 10.1111/jdv.18074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Accepted: 02/17/2022] [Indexed: 11/28/2022]
Affiliation(s)
- E. Rostagno
- Pediatric Oncology and Hematology Unit IRCCS Azienza Ospedaliero Universitaria di Bologna Via Massarenti 11 ‐ 40138 Bologna Italy
| | - A. Campanati
- Dermatology Unit Department of Clinical and Molecular Sciences United Hospitals of Ancona and Polytechnic Marche University Via Conca 70 ‐ 60200 Ancona Italy
| | - N. Mordini
- Hematology Division Azienda Ospedaliera S. Croce e Carle Via Coppino 26 ‐ 12100 Cuneo Italy
| | - C. Cannici
- Hematology Unit AO SS Antonio e Biagio e Cesare Arrigo di Alessandira Via Venezia 16 ‐ 15121 Alessandria Italy
| | - M. Cioce
- UOC SITRA Fondazione Policlinico Universitario A. Gemelli – IRCCS Largo Agostino Gemelli 00168 Roma Italy
| | - V. De Cecco
- Trapianto Emopoietico e Terapia Cellulare Ospedale Pediatrico Bambino Gesù Piazza di Sant'Onofrio 4 ‐ 00165 Roma Italy
| | - E. Samarani
- Unit of Blood Diseases and Stem Cell Transplantation Department of Clinical Oncology ASST Spedali Civili di Brescia Piazzale Spedali Civili 1 ‐ 25123 Brescia Italy
| | - R. Foà
- Department of Translational and Precision Medicine Sapienza University of Rome Via Benevento 6 ‐ 00165 Italy
| | - A. Olivieri
- Clinic of Hematology United Hospitals of Ancona and Polytechnic Marche University Via Conca 71 ‐ 60126 Ancona Italy
| | - S. Botti
- Hematology Unit Azienda USL‐IRCCS Reggio Emilia Viale Risorgimento 80 42123 Reggio Emilia Italy
| |
Collapse
|
5
|
Pulsoni A, Tosti ME, Ferrero S, Luminari S, Dondi A, Liberati AM, Cenfra N, Renzi D, Zanni M, Boccomini C, Ferreri AJ, Rattotti S, Zilioli VR, Bernuzzi P, Bolis S, Musuraca G, Nassi L, Perrone T, Stelitano C, Anastasia A, Corradini P, Partesotti G, Re F, Cencini E, Mannarella C, Mannina D, Molinari AL, Tani M, Annechini G, Assanto GM, Grapulin L, Guarini A, Cavalli M, De Novi LA, Ciabatti E, Mantoan B, Della Starza I, Arcaini L, Ricardi U, Gattei V, Galimberti S, Ladetto M, Foà R, Del Giudice I. UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.31_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Pulsoni
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - M. E. Tosti
- Istituto Superiore di Sanità National Center for Global Health Roma Italy
| | - S. Ferrero
- Hematology Division University of Torino/AOU "Città della Salute e della Scienza di Torino" Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - S. Luminari
- Hematology Unit Arcispedale S. Maria Nuova, Azienda Unità Sanitaria Locale ‐ IRCCS, University of Modena and Reggio Emilia Reggio Emilia Italy
| | - A. Dondi
- Fondazione Italiana Linfomi Onlus, (FIL) Modena Italy
| | - A. M. Liberati
- A.O. Santa Maria Terni, University of Perugia Perugia Italy
| | - N. Cenfra
- Hematology Unit, S. Maria Goretti Hospital AUSL Latina Latina Italy
| | - D. Renzi
- Hematology and Stem Cells Transplantation Unit IRCCS Istituto Nazionale dei Tumori Regina Elena Roma Italy
| | - M. Zanni
- Division of Hematology, SS. Antonio e Biagio Hospital Alessandria Italy
| | - C. Boccomini
- Hematology Department Città della Salute e della Scienza Torino Italy
| | - A. J. Ferreri
- Lymphoma Unit IRCCS San Raffaele Scientific Institute Department of Onco‐Haematology Milano Italy
| | - S. Rattotti
- Division of Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy
| | - V. R. Zilioli
- Division of Hematology ASST Grande Ospedale Metropolitano Niguarda Milano Italy
| | - P. Bernuzzi
- Hematology Unit, Guglielmo da Saliceto Hospital Department of Onco‐Hematology Piacenza Italy
| | - S. Bolis
- Hematology Department ASST San Gerardo University Hospital Monza Italy
| | - G. Musuraca
- Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori” Meldola (FC) Italy
| | - L. Nassi
- Division of Hematology University of Eastern Piedmont Department of Translational Medicine Novara Italy
| | - T. Perrone
- Unit of Hematology with Transplantation University of Bari, Dept. of Emergency and Organ Transplantation Bari Italy
| | - C. Stelitano
- Department of Haematology Azienda Ospedaliera Bianchi Melacrino Morelli Reggio Calabria Italy
| | - A. Anastasia
- Hematology, ASST Spedali Civili di Brescia Brescia Italy
| | - P. Corradini
- Division of Hematology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milano Italy
| | - G. Partesotti
- Onco‐Hematology Department Nuovo ospedale civile of Sassuolo Sassuolo Italy
| | - F. Re
- Hematology Clinic, A.O.U. di Parma Parma Italy
| | - E. Cencini
- Unit of Hematology Azienda Ospedaliera Universitaria Senese & University of Siena Siena Italy
| | - C. Mannarella
- Hematology Unit "Madonna delle Grazie" Hospital Matera Italy
| | - D. Mannina
- Department of Hematology Azienda Ospedaliera Papardo Messina Italy
| | | | - M. Tani
- Hematology Unit Santa Maria delle Croci Hospital Ravenna Italy
| | - G. Annechini
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - G. M. Assanto
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. Grapulin
- Department of Radiotherapy Policlinico Umberto I, Sapienza University Roma Italy
| | - A. Guarini
- Hematology, Sapienza University Department of Molecular Medicine Roma Italy
| | - M. Cavalli
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. A. De Novi
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - E. Ciabatti
- Section of Hematology, University of Pisa Department of Clinical and Experimental Medicine Pisa Italy
| | - B. Mantoan
- Hematology Division University of Torino Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - I. Della Starza
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo University of Pavia, Department of Molecular Medicine Pavia Italy
| | - U. Ricardi
- Radiation Oncology, University of Turin Department of Oncology Torino Italy
| | - V. Gattei
- Clinical and Experimental Onco‐Hematology Unit CRO Aviano National Cancer Institute Aviano Italy
| | - S. Galimberti
- Section of Hematology University of Pisa, Department of Clinical and Experimental Medicine Pisa Italy
| | - M. Ladetto
- Hematology, Az Ospedaliera Santi Antonio e Biagio e Cesare Arrigo Università del Piemonte Orientale Alessandria Italy
| | - R. Foà
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - I. Del Giudice
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| |
Collapse
|
6
|
Visentin A, Mauro FR, Cibien F, Vitale C, Reda G, Fresa A, Ciolli S, Pietrasanta D, Marchetti M, Murru R, Gentile M, Rigolin GM, Quaglia FM, Scarfò L, Sportoletti P, Pravato S, Romano Gargarella L, Facco M, Piazza F, Marchetti M, Coscia M, Laurenti L, Molica S, Pizzolo G, Foà R, Cuneo A, Trentim L. EFFICACY AND DISCONTINUATION RATE OF IBRUTINIB IN TREATMENT NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH TP53 ABNORMALITIES. A REAL‐LIFE CAMPUS CLL STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.46_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Visentin
- Hematology and Clinical Immunology Unit, Department of Medicine University of Padova Padova Italy
| | - F. R. Mauro
- Hematology Unit, Department of Translational and Precision Medicine Sapienza" University Rome Italy
| | - F. Cibien
- Hematology Unit Ca’ Foncello Hospital Treviso Italy
| | - C. Vitale
- Department of Molecular Biotechnology and Health Sciences University of Torino and Division of Hematology A.O.U. Città della Salute e della Scienza di Torino Torino Italy
| | - G. Reda
- Hematology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Milan Italy
| | - A. Fresa
- Hematology Institute Fondazione Policlinico Universitario Agostino Gemelli IRCSS Roma Italy
| | - S. Ciolli
- Hematology Unit, Careggi Hospital University of Florence Florence Italy
| | - D. Pietrasanta
- Division of Hematology A.O. SS Antonio e Biagio and Cesare Arrigo Alessandria Italy
| | - M. Marchetti
- Division of Hematology A.O. SS Antonio e Biagio and Cesare Arrigo Alessandria Italy
| | - R. Murru
- Hematology and Stem Cell Transplantation Unit Ospedale A. Businco, ARNAS “G. Brotzu Cagliari Italy
| | - M. Gentile
- Hematology unit, Department of Hemato‐Oncology Annunziata Hospital Cosenza Italy
| | - G. M. Rigolin
- Hematology section, Department of Medical Sciences Azienda Ospedaliera‐Universitaria, Arcispedale S. Anna, University of Ferrara Ferrara Italy
| | - F. M. Quaglia
- Department of Medicine, Section of Hematology University of Verona & Azienda Ospedaliera Universitaria Integrata Verona Italy
| | - L. Scarfò
- Strategic program on CLL University health and Science “San Raffaele Milan Italy
| | - P. Sportoletti
- Hematology and Clinical Immunology unit University of Perugia Perugia Italy
| | - S. Pravato
- Hematology and Clinical Immunology Unit, Department of Medicine University of Padova Padova Italy
| | - L. Romano Gargarella
- Hematology and Clinical Immunology Unit, Department of Medicine University of Padova Padova Italy
| | - M. Facco
- Hematology and Clinical Immunology Unit, Department of Medicine University of Padova Padova Italy
| | - F. Piazza
- Hematology and Clinical Immunology Unit, Department of Medicine University of Padova Padova Italy
| | - M. Marchetti
- Division of Hematology A.O. SS Antonio e Biagio and Cesare Arrigo Alessandria Italy
| | - M. Coscia
- Department of Molecular Biotechnology and Health Sciences University of Torino and Division of Hematology A.O.U. Città della Salute e della Scienza di Torino Torino Italy
| | - L. Laurenti
- Hematology Institute Fondazione Policlinico Universitario Agostino Gemelli IRCSS Roma Italy
| | - S. Molica
- Department Hematology‐Oncology Azienda Ospedaliera Pugliese‐Ciaccio Catanzaro Italy
| | - G. Pizzolo
- Department of Medicine, Section of Hematology University of Verona & Azienda Ospedaliera Universitaria Integrata Verona Italy
| | - R. Foà
- Hematology Unit, Department of Translational and Precision Medicine Sapienza" University Rome Italy
| | - A. Cuneo
- Hematology section, Department of Medical Sciences Azienda Ospedaliera‐Universitaria, Arcispedale S. Anna, University of Ferrara Ferrara Italy
| | - L. Trentim
- Hematology and Clinical Immunology Unit, Department of Medicine University of Padova Padova Italy
| |
Collapse
|
7
|
Raponi S, Del Giudice I, Marinelli M, Wang J, Cafforio L, Ilari C, Piciocchi A, Messina M, Bonina S, Tavolaro S, Bordyuh M, Mariglia P, Peragine N, Mauro FR, Chiaretti S, Molica S, Gentile M, Visentin A, Trentin L, Rigolin GM, Cuneo A, Diop F, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R. Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. Ann Oncol 2019; 29:966-972. [PMID: 29365086 DOI: 10.1093/annonc/mdy021] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Chronic lymphocytic leukemia (CLL) has a heterogeneous clinical course. Beside patients requiring immediate treatment, others show an initial indolent phase followed by progression and others do not progress for decades. The latter two subgroups usually display mutated IGHV genes and a favorable FISH profile. Patients and methods Patients with absence of disease progression for over 10 years (10-34) from diagnosis were defined as ultra-stable CLL (US-CLL). Forty US-CLL underwent extensive characterization including whole exome sequencing (WES), ultra-deep sequencing and copy number aberration (CNA) analysis to define their unexplored genetic landscape. Microarray analysis, comparing US-CLL with non-US-CLL with similar immunogenetic features (mutated IGHV/favorable FISH), was also carried out to recognize US-CLL at diagnosis. Results WES was carried out in 20 US-CLL and 84 non-silent somatic mutations in 78 genes were found. When re-tested in a validation cohort of 20 further US-CLL, no recurrent lesion was identified. No clonal mutations of NOTCH1, BIRC3, SF3B1 and TP53 were found, including ATM and other potential progression driving mutations. CNA analysis identified 31 lesions, none with known poor prognostic impact. No novel recurrent lesion was identified: most cases showed no lesions (38%) or an isolated del(13q) (31%). The expression of 6 genes, selected from a gene expression profile analysis by microarray and quantified by droplet digital PCR on a cohort of 79 CLL (58 US-CLL and 21 non-US-CLL), allowed to build a decision-tree capable of recognizing at diagnosis US-CLL patients. Conclusions The genetic landscape of US-CLL is characterized by the absence of known unfavorable driver mutations/CNA and of novel recurrent genetic lesions. Among CLL patients with favorable immunogenetics, a decision-tree based on the expression of 6 genes may identify at diagnosis patients who are likely to maintain an indolent disease for decades.
Collapse
Affiliation(s)
- S Raponi
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - I Del Giudice
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - M Marinelli
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - J Wang
- Division of Life Science and Department of Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong
| | - L Cafforio
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - C Ilari
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - A Piciocchi
- GIMEMA Data Centre, GIMEMA Foundation, Rome, Italy
| | - M Messina
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Bonina
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Tavolaro
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - M Bordyuh
- Department of Systems Biology, Columbia University, New York, USA; Department of, Biomedical Informatics, Columbia University, New York, USA
| | - P Mariglia
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - N Peragine
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - F R Mauro
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Chiaretti
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Molica
- Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy
| | - M Gentile
- Hematology Uni, Department of Hemato-Oncology, Ospedale Annunziata, Cosenza, Italy
| | - A Visentin
- Hematology Sectio, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
| | - L Trentin
- Hematology Sectio, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
| | - G M Rigolin
- Hematology Sectio, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - A Cuneo
- Hematology Sectio, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - F Diop
- Division of Hematolog, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - D Rossi
- Department of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland
| | - G Gaidano
- Division of Hematolog, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - A Guarini
- Department of Molecular Medicine, Sapienza University, Rome, Italy
| | - R Rabadan
- Department of Systems Biology, Columbia University, New York, USA; Department of, Biomedical Informatics, Columbia University, New York, USA
| | - R Foà
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
| |
Collapse
|
8
|
Tiacci E, De Carolis L, Simonetti E, Zaja F, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani P, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Visani G, Foà R, Falini B. THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.72_2629] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- E. Tiacci
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - L. De Carolis
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - E. Simonetti
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - F. Zaja
- Hematology Unit; Azienda Sanitaria Universitaria Integrata-Ospedale Maggiore; Trieste Italy
| | - M. Capponi
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - A. Ambrosetti
- Department of Medicine; Section of Hematology; Verona Italy
| | - E. Lucia
- Hematology Unit; Ospedale di Cosenza; Cosenza Italy
| | - A. Antolino
- Hematology Unit, Department of Transfusional Medicine - SIMMT; Maria Paternò-Arezzo Hospital; Ragusa Italy
| | - A. Pulsoni
- Hematology Unit, Department of Translational and Precision Medicine; "Sapienza" University of Rome; Roma Italy
| | - S. Ferrari
- Department of Hematology; Spedali Civili di Brescia; Brescia Italy
| | - P. Zinzani
- Institute of Hematology, Policlinico Sant'Orsola-Malpighi; University of Bologna; Bologna Italy
| | - L. Rigacci
- Hematology and Stem Cell Transplant Unit; AO San Camillo Forlanini; Roma Italy
| | - G. Gaidano
- Department of Translational Medicine, Division of Hematology; Amedeo Avogadro University of Eastern Piedmont; Novara Italy
| | | | | | - P. Falcucci
- Hematology Unit; Ospedale di Ronciglione; Viterbo Italy
| | - G. Visani
- Hematology Unit; Ospedale di Pesaro; Pesaro Italy
| | - R. Foà
- Hematology Unit, Department of Translational and Precision Medicine; "Sapienza" University of Rome; Roma Italy
| | - B. Falini
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| |
Collapse
|
9
|
Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter M, Herling C, De Paoli L, Delgado J, Gentile M, Doubek M, Mauro F, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Moia R, Gerber B, Zucca E, Ghielmini M, Cavalli F, Stüssi G, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foà R, Pospisilova S, Morabito F, Wierda W, Montserrat E, Gaidano G, Hallek M, Rossi D. INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A). Hematol Oncol 2019. [DOI: 10.1002/hon.51_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Condoluci
- Experimental Hematology; Institute of Oncology Research; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - L. Terzi di Bergamo
- Experimental Hematology; Institute of Oncology Research; Bellinzona Switzerland
| | - P. Langerbeins
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - M. Hoechstetter
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - C. Herling
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - L. De Paoli
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - J. Delgado
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - M. Gentile
- Hematology; Azienda Ospedaliera (AO) of Cosenza; Cosenza Italy
| | - M. Doubek
- Hematology and Oncology; University Hospital of Brno; Brno Czech Republic
| | - F.R. Mauro
- Hematology; Sapienza University; Rome Italy
| | - G. Chiodin
- Hematology; Southampton University; Southampton United Kingdom
| | - M. Mattsson
- Immunology; Genetics and Pathology, Uppsala University; Uppsala Sweden
| | - J. Bahlo
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - G. Cutrona
- Hematology; IRCCS Ospedale Policlinico San Martino; Genoa Italy
| | - J. Kotaskova
- Hematology and Oncology; University Hospital of Brno; Brno Czech Republic
| | - C. Deambrogi
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - R. Moia
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - B. Gerber
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - E. Zucca
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - M. Ghielmini
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Cavalli
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - G. Stüssi
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Neri
- Hematology; University of Milan; Milan Italy
| | | | - R. Rosenquist
- Immunology; Genetics and Pathology, Uppsala University; Uppsala Sweden
| | - F. Forconi
- Hematology; Southampton University; Southampton United Kingdom
| | - R. Foà
- Hematology; Sapienza University; Rome Italy
| | - S. Pospisilova
- Hematology and Oncology; University Hospital of Brno; Brno Czech Republic
| | - F. Morabito
- Hematology; Augusta Victoria Hospital; Jerusalem Israel
| | - W.G. Wierda
- MD Anderson Cancer Center; University of Texas; Houston United States
| | - E. Montserrat
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - G. Gaidano
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - M. Hallek
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - D. Rossi
- Experimental Hematology; Institute of Oncology Research; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| |
Collapse
|
10
|
Affiliation(s)
- A Cuneo
- Department of Radiotherapy, Hematology Unit, University of Ferrara, Ferrara
| | - R Foà
- Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| |
Collapse
|
11
|
Abstract
A human acute T lymphoblastic leukemia line (PF-382) was serially transplanted into nude mice. No takes were observed in untreated nude mice, whereas solid tumors were observed in splenectomized and total body, sublethally irradiated mice. The minimal tumor-inducing dose and the latency time remained unchanged after the third and fifth serial transplants. Moreover, leukemic cells recovered from the 8th in vivo passages displayed the same differentiation antigens and chromosomal markers as the in vitro PF-382 cell line used for the first transplant. This stable and well-characterized experimental system could be a new model for T-lymphocyte differentiation and immune-reactivity against human leukemias.
Collapse
|
12
|
Lauria F, Raspadori D, Foà R, Tazzari PL, Lusso P, Fierro MT, Matera L, Baccarani M, Tura S. Normal T-Lymphocyte Function in Patients with Hodgkin's Disease in Long-Lasting Remission. Tumori 2018; 72:75-80. [PMID: 2937189 DOI: 10.1177/030089168607200111] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
In 18 patients with Hodgkin's disease (HD) in long-lasting remission (more than 5 years), the distribution of circulating T-lymphocytes was analyzed using a series of monoclonal antibodies (OKT3, T4, T8, Leu-7, Leu-11 and T10) and correlated with cell function (helper capacity in a pokeweed mitogen system and natural killer (NK) activity). A reduced proportion of OKT4 (helper/inducer)-positive cells associated with a normal absolute number was consistently accompanied by a significant increase (p < 0.005) in the proportion and absolute number of OKT8 (suppressor/cytotoxic)-positive cells. The OKT4-positive cells, despite their moderate percentage reduction, showed normal helper activity. A more extensive characterization of the lymphoid population in these patients documented a preserved cytotoxic function in a 51Cr release assay and increased proportion of cells expressing NK-associated antigens (Leu-7, Leu-11, OKT10) with a high number of cells coexpressing OKT8 and Leu-7. It is suggested that in patients with Hodgkin's disease in long-lasting remission no laboratory (or clinical) evidence of cellular immunodeficiency can be documented.
Collapse
|
13
|
Giudice ID, Rigolin GM, Raponi S, Cafforio L, Ilari C, Wang J, Bordyuh M, Piciocchi A, Marinelli M, Nanni M, Tavolaro S, Filetti M, Bardi A, Tammiso E, Volta E, Negrini M, Saccenti E, Mauro FR, Rossi D, Gaidano G, Guarini A, Rabadan R, Cuneo A, Foà R. Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. Leukemia 2017; 32:543-546. [PMID: 28924243 DOI: 10.1038/leu.2017.292] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- I Del Giudice
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - G M Rigolin
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - S Raponi
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - L Cafforio
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - C Ilari
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - J Wang
- Divisions of Life Science and Biomedical Engineering, Hong Kong University of Science and Technology, Hong Kong, China
| | - M Bordyuh
- Department of Biomedical Informatics, Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, USA
| | - A Piciocchi
- GIMEMA Data Centre, GIMEMA Foundation, Rome, Italy
| | - M Marinelli
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - M Nanni
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - S Tavolaro
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - M Filetti
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - A Bardi
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - E Tammiso
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - E Volta
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - M Negrini
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - E Saccenti
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - F R Mauro
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - D Rossi
- Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland
| | - G Gaidano
- Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | - A Guarini
- Department of Molecular Medicine, Sapienza University, Rome, Italy
| | - R Rabadan
- Department of Biomedical Informatics, Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, USA
| | - A Cuneo
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - R Foà
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| |
Collapse
|
14
|
Bernson E, Hallner A, Sander FE, Wilsson O, Werlenius O, Rydström A, Kiffin R, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén FB. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia. Leukemia 2017; 31:2552-2559. [PMID: 28529313 PMCID: PMC5729331 DOI: 10.1038/leu.2017.151] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Revised: 05/03/2017] [Accepted: 05/09/2017] [Indexed: 12/23/2022]
Abstract
Interactions between killer-immunoglobulin-like receptors (KIRs) and their HLA class I ligands are instrumental in natural killer (NK) cell regulation and protect normal tissue from NK cell attack. Human KIR haplotypes comprise genes encoding mainly inhibitory receptors (KIR A) or activating and inhibitory receptors (KIR B). A substantial fraction of humans lack ligands for inhibitory KIRs (iKIRs), that is, a ‘missing ligand’ genotype. KIR B/x and missing ligand genotypes may thus give rise to potentially autoreactive, unlicensed NK cells. Little is known regarding the impact of such genotypes in untransplanted acute myeloid leukemia (AML). For this study, NK cell phenotypes and KIR/HLA genotypes were determined in 81 AML patients who received immunotherapy with histamine dihydrochloride and low-dose IL-2 for relapse prevention (NCT01347996). We observed that presence of unlicensed NK cells impacted favorably on clinical outcome, in particular among patients harboring functional NK cells reflected by high expression of the natural cytotoxicity receptor (NCR) NKp46. Genotype analyses suggested that the clinical benefit of high NCR expression was restricted to patients with a missing ligand genotype and/or a KIR B/x genotype. These data imply that functional NK cells are significant anti-leukemic effector cells in patients with KIR/HLA genotypes that favor NK cell autoreactivity.
Collapse
Affiliation(s)
- E Bernson
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - A Hallner
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - F E Sander
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - O Wilsson
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - O Werlenius
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.,Department of Hematology, University of Gothenburg, Gothenburg, Sweden
| | - A Rydström
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - R Kiffin
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - M Brune
- Department of Hematology, University of Gothenburg, Gothenburg, Sweden
| | - R Foà
- Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - J Aurelius
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.,Department of Hematology, University of Gothenburg, Gothenburg, Sweden
| | - A Martner
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - K Hellstrand
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - F B Thorén
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| |
Collapse
|
15
|
Soverini S, De Benedittis C, Papayannidis C, Polakova KM, Venturi C, Russo D, Bresciani P, Iurlo A, Mancini M, Vitale A, Chiaretti S, Foà R, Abruzzese E, Sorà F, Kohlmann A, Haferlach T, Baccarani M, Cavo M, Martinelli G. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. Leukemia 2016; 30:1615-9. [DOI: 10.1038/leu.2016.17] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
16
|
Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, Gentile M, Morabito F, Coscia M, Bellò M, Sacchetti GM, Rossi D, Laurenti L, Autore F, Campanelli M, Trastulli F, Nicolai E, Riminucci M, Gaidano G, Guarini A, Gallamini A, Foà R. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia 2015; 29:1360-5. [DOI: 10.1038/leu.2015.21] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2014] [Revised: 10/25/2014] [Accepted: 12/10/2014] [Indexed: 11/09/2022]
|
17
|
Santoro C, Di Mauro R, Baldacci E, De Angelis F, Abbruzzese R, Barone F, Bochicchio RA, Ferrara G, Guarini A, Foà R, Mazzucconi MG. Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre. Haemophilia 2015; 21:496-501. [DOI: 10.1111/hae.12628] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/08/2014] [Indexed: 01/08/2023]
Affiliation(s)
- C. Santoro
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - R. Di Mauro
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - E. Baldacci
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - F. De Angelis
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - R. Abbruzzese
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - F. Barone
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - R. A. Bochicchio
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - G. Ferrara
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - A. Guarini
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - R. Foà
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - M. G. Mazzucconi
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| |
Collapse
|
18
|
Varano G, Foà R, Bonomo G, Monfardini L, Vigna P, Musi G, Orsi F. Percutaneous Radiofrequency Ablation (RFA) for Renal Tumors Larger than 4 cm. J Vasc Interv Radiol 2015. [DOI: 10.1016/j.jvir.2014.10.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
19
|
Varano G, Monfardini L, Bonomo G, Vigna P, Foà R, Musi G, Orsi F. Radiofrequency Thermal Ablation of Isolated Local Recurrence after Surgery for Renal Cell Carcinoma. J Vasc Interv Radiol 2015. [DOI: 10.1016/j.jvir.2014.10.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
20
|
Piva R, Deaglio S, Famà R, Buonincontri R, Scarfò I, Bruscaggin A, Mereu E, Serra S, Spina V, Brusa D, Garaffo G, Monti S, Dal Bo M, Marasca R, Arcaini L, Neri A, Gattei V, Paulli M, Tiacci E, Bertoni F, Pileri SA, Foà R, Inghirami G, Gaidano G, Rossi D. The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia 2014; 29:503-7. [DOI: 10.1038/leu.2014.294] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
21
|
Iori A, Ferretti A, Gentile G, Gabrielli S, Perrone S, Barberi W, Torelli G, Natalino F, Scalzulli E, Totino V, Foà R, Cancrini G, Girmenia C. Strongyloides stercoralisinfection in allogeneic stem cell transplant: a case report and review of the literature. Transpl Infect Dis 2014; 16:625-30. [DOI: 10.1111/tid.12239] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2013] [Revised: 01/31/2014] [Accepted: 02/18/2014] [Indexed: 11/27/2022]
Affiliation(s)
- A.P. Iori
- Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa; Azienda Policlinico Umberto I; Sapienza University; Rome Italy
| | - A. Ferretti
- Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa; Azienda Policlinico Umberto I; Sapienza University; Rome Italy
| | - G. Gentile
- Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa; Azienda Policlinico Umberto I; Sapienza University; Rome Italy
| | - S. Gabrielli
- Dipartimento di Sanità Pubblica e Malattie Infettive; Azienda Policlinico Umberto I; Sapienza University; Rome Italy
| | - S. Perrone
- Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa; Azienda Policlinico Umberto I; Sapienza University; Rome Italy
| | - W. Barberi
- Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa; Azienda Policlinico Umberto I; Sapienza University; Rome Italy
| | - G.F. Torelli
- Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa; Azienda Policlinico Umberto I; Sapienza University; Rome Italy
| | - F. Natalino
- Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa; Azienda Policlinico Umberto I; Sapienza University; Rome Italy
| | - E. Scalzulli
- Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa; Azienda Policlinico Umberto I; Sapienza University; Rome Italy
| | - V. Totino
- Dipartimento di Sanità Pubblica e Malattie Infettive; Azienda Policlinico Umberto I; Sapienza University; Rome Italy
| | - R. Foà
- Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa; Azienda Policlinico Umberto I; Sapienza University; Rome Italy
| | - G. Cancrini
- Dipartimento di Sanità Pubblica e Malattie Infettive; Azienda Policlinico Umberto I; Sapienza University; Rome Italy
| | - C. Girmenia
- Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa; Azienda Policlinico Umberto I; Sapienza University; Rome Italy
| |
Collapse
|
22
|
De Angelis F, Di Rocco A, Minotti C, Valesini G, Cartoni C, Riminucci M, Conti F, Finolezzi E, Armiento D, Grammatico S, Massaro L, Fama A, Colafigli G, Viccarone C, Foà R, Martelli M. Corrigendum to “Atypical presentation of anaplastic large T-cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept. A case report and literature review” [Leuk. Res. 36 (2012) e199–e201]. Leuk Res 2013. [DOI: 10.1016/j.leukres.2013.07.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
23
|
Capria S, De Angelis F, Gentile G, Trisolini S, Brocchieri S, Canichella M, Chiusolo P, Micozzi A, Foà R, Meloni G. Complete remission obtained with azacitidine in a patient with concomitant therapy related myeloid neoplasm and pulmonary mucormycosis. Mediterr J Hematol Infect Dis 2013; 5:e2013048. [PMID: 23936619 PMCID: PMC3736875 DOI: 10.4084/mjhid.2013.048] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2013] [Accepted: 06/11/2013] [Indexed: 12/03/2022] Open
Abstract
Mucormycosis is the third cause of invasive mycosis after candidiasis and aspergillosis in AML patients, representing a poor prognostic factor associated with a high rate of fatal outcome. We report a case of a patient with AML and a concomitant pulmonary mucormycosis at diagnosis, who obtained a complete remission both of her AML and of the fungal infection. The incidence of the infection at the onset of leukemia is extremely unusual, and, to our knowledge, the sporadic cases reported in the literature are included in heterogeneous series retrospectively examined. In our case, Liposomal Amphotericin B as single agent appeared incapable of controlling the infection, so anti-infective therapy was intensified with posaconazole and simultaneously antileukemic treatment with 5-azacitidine was started, with the understanding that the only antifungal treatment would not have been able to keep the infection under control for a long time if not associated with a reversal of neutropenia related to the disease. We observed a progressive improvement of the general conditions, a healing of pneumonia and a complete remission of the leukemic disease, suggesting that a careful utilization of the new compounds available today, in terms of both antifungal and antileukemic treatment, may offer a curative chance a patient who would have otherwise been considered unfit for a potentially curative therapeutic strategy.
Collapse
Affiliation(s)
- S. Capria
- Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy
| | - F. De Angelis
- Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy
| | - G. Gentile
- Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy
| | - S.M. Trisolini
- Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy
| | - S. Brocchieri
- Department of Radiologic Sciences, Azienda Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy
| | - M. Canichella
- Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy
| | - P. Chiusolo
- Department of Hematology, Catholic University of the Sacred Heart, Rome, Italy
| | - A. Micozzi
- Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy
| | - R. Foà
- Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy
| | - G. Meloni
- Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy
| |
Collapse
|
24
|
De Angelis F, Foà R. Follicular lymphoma. Exp Oncol 2012; 34:380-383. [PMID: 23303004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Affiliation(s)
- F De Angelis
- Hematology Division, Department of Cellular Biotechnologies and Hematology, Univerity of Rome Sapienza, Rome, Italy
| | | |
Collapse
|
25
|
Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Cresta S, Famà R, Deambrogi C, Greco M, Fangazio M, Ciardullo C, Piranda D, Casaluci GM, Messina M, Giudice ID, Chiaretti S, Marinelli M, Guarini A, Foà R, Gaidano G. The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1. Leuk Suppl 2012; 1:S26-8. [PMID: 27175239 DOI: 10.1038/leusup.2012.16] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Next-generation whole-exome sequencing has revealed two novel genes, namely NOTCH1 and SF3B1, whose mutations predict poor outcome and preferentially associate with chemorefractory chronic lymphocytic leukemia (CLL). Analysis of 539 CLL cases documents that NOTCH1 mutations i) represent one of the most frequent cancer gene mutations involved at presentation; ii) cluster with cases harboring trisomy 12 and tend to be mutually exclusive with TP53 disruption among genetic subgroups; iii) identify high-risk patients showing poor survival similar to that associated with TP53 abnormalities; and iv) exert a prognostic role independent of widely accepted clinical and genetic risk factors. Mutations of SF3B1, a splicing factor that is a critical component of the spliceosome, recurrently associate with fludarabine-refractory CLL, occur at a low rate at CLL presentation and have a minor role in Richter transformation, corroborating the notion that CLL histological shift is molecularly distinct from chemorefractory progression without the Richter transformation.
Collapse
Affiliation(s)
- D Rossi
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - S Rasi
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - V Spina
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - A Bruscaggin
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - S Monti
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - S Cresta
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - R Famà
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - C Deambrogi
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - M Greco
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - M Fangazio
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - C Ciardullo
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - D Piranda
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - G M Casaluci
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - M Messina
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome, Italy
| | - I D Giudice
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome, Italy
| | - S Chiaretti
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome, Italy
| | - M Marinelli
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome, Italy
| | - A Guarini
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome, Italy
| | - R Foà
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy; Fondazione Eleonora Lorillard Spencer Cenci, Sapienza University, Rome, Italy
| | - G Gaidano
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| |
Collapse
|
26
|
Molica S, Gentile M, Mauro FR, Brugiatelli M, Federico M, Sperduti I, Neri A, Ferrarini M, Foà R, Morabito F. An increased number of individuals with clinically recognized monoclonal B-cell lymphocytosis characterizes a recent database of chronic lymphocytic leukemia Rai stage 0. Acta Haematol 2012; 127:149-51. [PMID: 22262125 DOI: 10.1159/000333621] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2011] [Accepted: 09/25/2011] [Indexed: 12/18/2022]
Affiliation(s)
- S Molica
- Dipartimento di Emato-Oncologia, Azienda Ospedaliera di Catanzaro, Italia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
|
28
|
Biondo F, Matturro A, Santoro C, Leporace A, D'Elia G, Baldacci E, Pignoloni P, Pulsoni A, Foà R, Mazzucconi M. Remission of acquired von Willebrand syndrome after successful treatment of gastric MALT lymphoma. Haemophilia 2011; 18:e34-5. [PMID: 22059776 DOI: 10.1111/j.1365-2516.2011.02681.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
29
|
Hehlmann R, Simonsson B, Baccarani M, Grimwade D, Apperley J, Barbui T, Bene MC, Buchner T, de Witte TJ, Foà R, Haferlach C, Hallek M, Hasford J, Hochhaus A, Hoelzer D, Ljungman P, Niederwieser D, Sanz MA, Saussele S. LeukemiaNet: A transnational model for cooperative leukemia research. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.6556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Cafolla A, Melizzi R, Baldacci E, Pignoloni P, Dragoni F, Campanelli M, Caraccini R, Foà R. "Zeus" a new oral anticoagulant therapy dosing algorithm: a cohort study. Thromb Res 2011; 128:325-30. [PMID: 21600633 DOI: 10.1016/j.thromres.2011.04.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2011] [Revised: 03/31/2011] [Accepted: 04/04/2011] [Indexed: 11/30/2022]
Abstract
The demand for oral anticoagulant therapy (OAT) has constantly increased during the last ten years with an extended use of computer assistance. Many mathematical algorithms have been projected to suggest doses and time to next visit for patients on OAT. We designed a new algorithm: "Zeus". A "before-after" study was planned to compare the efficacy and safety of this algorithm dosing OAT with manual dosage decided by the same expert physicians according to the target of International Normalized Ratio (INR). The study analysed data of 1876 patients managed with each of the two modalities for eight months, with an interval of two years between them. The aim was to verify the increased quality of therapy by time spent in INR target and efficiency and safety of Zeus algorithm. Time in therapeutic range (TTR) was significantly (p < 0.0001) higher during the algorithm dosing period in comparison with the TTR during manual management period (62.3% vs 50.3%). The number of PT/INR tests above 5 was significantly (p < 0.001) reduced by algorithm suggested prescriptions in comparison with manual those (254 vs 537 times). The anticoagulant drug amount prescribed according to the algorithm suggestions was significantly (p < 0.0001) lower than that of the manual method. The number of clinical events observed in patients during the algorithm management time was significantly (p < 0.05) lower than that in those managed with the manual dosage. This study confirms the clinical utility of the computer-assisted OAT and shows the efficacy and safety of the Zeus algorithm.
Collapse
Affiliation(s)
- A Cafolla
- Dipartimento di Biotecnologie Cellulari ed Ematologia, Sapienza Università Roma, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Morschhauser F, Marlton P, Vitolo U, Lindén O, Seymour J, Crump M, Coiffier B, Foà R, Wassner E, Burger HU, Brennan B, Mendila M. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 2010; 21:1870-1876. [DOI: 10.1093/annonc/mdq027] [Citation(s) in RCA: 103] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
|
32
|
Österborg A, Foà R, Bezares RF, Dearden C, Dyer MJS, Geisler C, Lin TS, Montillo M, van Oers MHJ, Wendtner CM, Rai KR. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009; 23:1980-8. [DOI: 10.1038/leu.2009.146] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
33
|
Grammatico S, Elia L, Peluso A, Pedace L, Matarazzo M, Vitale A, Rago A, Pane F, Foà R, Cimino G. Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia. Leuk Res 2009; 33:e73-4. [DOI: 10.1016/j.leukres.2008.11.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2008] [Revised: 10/31/2008] [Accepted: 11/01/2008] [Indexed: 10/21/2022]
|
34
|
Coluzzi S, Giona F, De Nicolò MC, Amendola A, Arista MC, Neri A, Rea M, Chirletti P, Foà R, Girelli G. Response of AIHA to high dose intravenous immunoglobulins in a patient with ovarian teratoma. Eur J Clin Invest 2009; 39:531-2. [PMID: 19490062 DOI: 10.1111/j.1365-2362.2009.02134.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Iacobucci I, Storlazzi C, Lonetti A, Ferrari A, Messina M, Cilloni D, Papayannidis C, Baccarani M, Foà R, Martinelli G. IKZF1 (IKAROS) deletions as a prognostic marker in BCR-ABL1 positive acute lymphoblastic leukemia patients: A GIMEMA ALL WP Report. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.11005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11005 Expression of BCR-ABL1 in hematopoietic stem cells can alone induce a chronic myeloid leukemia (CML) but cooperating oncogenic lesions are required for the generation of a blastic leukemia. To identify oncogenic sub-microscopic lesions that cooperate with BCR-ABL1 to induce ALL, by high resolution single nucleotide polymorphism (SNP) arrays (250K NspI and SNP 6.0, Affymetrix) we studied 106 patients (pts) with de novo adult BCR-ABL1-positive ALL. The most frequent somatic copy number alteration was deletion on 7p12 of IKZF1 (68/106, 64%), which encodes the transcription factor Ikaros required for the earliest stages of lymphoid lineage commitment. We characterized and mapped all breakpoints in IKZF1 gene to recognize that two major deletions occur: the first one characterized by loss of exons 4–7 (44%) and due to breakpoints in introns 3 and 7; the second one characterized by removal of exons 2–7 (19%) and due to a variable pattern of breakpoints in introns 1 and 7. In two pts we had both Δ2–7 and Δ4–7 deletions and in one we identified a deletion of all IKZF1 gene and part of GRB10. A variable number of nucleotides (patient-specific) were inserted at the conjunction and maintained with fidelity at the time of relapse. Gene expression profiling analysis of pts with IKZF1 deletion vs wild-type pts identified a unique signature characterized by a down-regulation of genes involved in pre-B-cell differentiation (e.g. VPREB1, VPREB3, IGLL3, BLK), demonstrating that genomic IKZF1 alterations have a strong impact on trascriptoma and contribute to an impaired B-cell differentiation. Univariate analysis showed that the IKZF1 deletion is a negative prognostic marker influencing the cumulative incidence of relapse (10.1 months for pts with deletion vs 56.1 months for wild-type pts, p=0.0103) and disease-free survival (DFS) (10.1 months vs 32.1 months, respectively, p=0.0229). The negative prognostic impact of the IKZF1 deletion on DFS was also confirmed by multivariate analysis (p=0.0445). In conclusion, deletion of IKZF1 is an important event in the development of BCR-ABL1 B-progenitor ALL which significantly influences clinical outcome. Supported by European LeukemiaNet, AIL, AIRC, FIRB 2006, Strategico di Ateneo, GIMEMA Onlus. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- I. Iacobucci
- Department of Hematology/Oncology Seràgnoli, University of Bologna, Bologna, Italy; Department of Genetics and Microbiology, University of Bari, Bari, Italy; Department of Cellular Biotechnology and Hematology, La Sapienza, Rome, Italy; Department of Clinical and Biological Science, Orbassano, Turin, Italy
| | - C. Storlazzi
- Department of Hematology/Oncology Seràgnoli, University of Bologna, Bologna, Italy; Department of Genetics and Microbiology, University of Bari, Bari, Italy; Department of Cellular Biotechnology and Hematology, La Sapienza, Rome, Italy; Department of Clinical and Biological Science, Orbassano, Turin, Italy
| | - A. Lonetti
- Department of Hematology/Oncology Seràgnoli, University of Bologna, Bologna, Italy; Department of Genetics and Microbiology, University of Bari, Bari, Italy; Department of Cellular Biotechnology and Hematology, La Sapienza, Rome, Italy; Department of Clinical and Biological Science, Orbassano, Turin, Italy
| | - A. Ferrari
- Department of Hematology/Oncology Seràgnoli, University of Bologna, Bologna, Italy; Department of Genetics and Microbiology, University of Bari, Bari, Italy; Department of Cellular Biotechnology and Hematology, La Sapienza, Rome, Italy; Department of Clinical and Biological Science, Orbassano, Turin, Italy
| | - M. Messina
- Department of Hematology/Oncology Seràgnoli, University of Bologna, Bologna, Italy; Department of Genetics and Microbiology, University of Bari, Bari, Italy; Department of Cellular Biotechnology and Hematology, La Sapienza, Rome, Italy; Department of Clinical and Biological Science, Orbassano, Turin, Italy
| | - D. Cilloni
- Department of Hematology/Oncology Seràgnoli, University of Bologna, Bologna, Italy; Department of Genetics and Microbiology, University of Bari, Bari, Italy; Department of Cellular Biotechnology and Hematology, La Sapienza, Rome, Italy; Department of Clinical and Biological Science, Orbassano, Turin, Italy
| | - C. Papayannidis
- Department of Hematology/Oncology Seràgnoli, University of Bologna, Bologna, Italy; Department of Genetics and Microbiology, University of Bari, Bari, Italy; Department of Cellular Biotechnology and Hematology, La Sapienza, Rome, Italy; Department of Clinical and Biological Science, Orbassano, Turin, Italy
| | - M. Baccarani
- Department of Hematology/Oncology Seràgnoli, University of Bologna, Bologna, Italy; Department of Genetics and Microbiology, University of Bari, Bari, Italy; Department of Cellular Biotechnology and Hematology, La Sapienza, Rome, Italy; Department of Clinical and Biological Science, Orbassano, Turin, Italy
| | - R. Foà
- Department of Hematology/Oncology Seràgnoli, University of Bologna, Bologna, Italy; Department of Genetics and Microbiology, University of Bari, Bari, Italy; Department of Cellular Biotechnology and Hematology, La Sapienza, Rome, Italy; Department of Clinical and Biological Science, Orbassano, Turin, Italy
| | - G. Martinelli
- Department of Hematology/Oncology Seràgnoli, University of Bologna, Bologna, Italy; Department of Genetics and Microbiology, University of Bari, Bari, Italy; Department of Cellular Biotechnology and Hematology, La Sapienza, Rome, Italy; Department of Clinical and Biological Science, Orbassano, Turin, Italy
| |
Collapse
|
36
|
Lonetti A, Iacobucci I, Ferrari A, Messina M, Cilloni D, Soverini S, Papayannidis C, Baccarani M, Foà R, Martinelli G. Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7049 Since the activation-induced cytidine deaminase (AID) enzyme can target non-immunoglobulin (Ig) genes and may even act as a genome-wide mutator, we investigated AID expression in BCR-ABL1-positive ALL and in chronic myeloid leukemia (CML) at the time of progression to blast crisis. On the 61 de novo adult BCR-ABL1-positive ALL patients (pts), AID mRNA and protein were detected in 36 (59%); their expression correlated with BCR-ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors at the time of remission. AID expression was also found in lymphoid blast crisis CML (50%), but not in myeloid lineage or in chronic phase CML. Different isoforms of AID were identified: 13/61 (21%) pts expressed the full-length isoform; 19/61 (31%) co-expressed the wild-type and different AID splice variants with deaminase activity (AIDΔE4a, with a 30 bp deletion of exon 4; AIDΔE4, with the exon 4 deletion; AIDins3, with the retention of intron 3–4); 4/61 (7%) expressed the AIDΔE3-E4 isoform without deaminase activity (deletion of exons 2 and 3). To investigate whether AID introduces DNA-single strand breaks, we performed a genome wide analysis by 250K NspI single nucleotide polymorphism (SNP) array. Patients who expressed wild-type AID had a higher number of alterations compared to AID-negative (median copy number alteration of 14 versus 4. respectively, p < 0.03). Recurring copy number abnormalities were identified in genes with an established role in leukemogenesis, such as IKZF1, CDKN2A, CDKN2B, PAX5, MELK, BTG1, and MDS1. Our findings show that BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that can act as mutator outside the Ig gene loci in promoting genetic instability in leukemia cells. Supported by: European LeukemiaNet, AIL, AIRC, FIRB 2006, Fondazione del Monte di Bologna e Ravenna, Strategico di Ateneo, GIMEMA Onlus. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Lonetti
- University of Bologna, Bologna, Italy; La Sapienza, Rome, Italy; San Luigi Gonzaga Hospital, Orbassano, Turin, Italy
| | - I. Iacobucci
- University of Bologna, Bologna, Italy; La Sapienza, Rome, Italy; San Luigi Gonzaga Hospital, Orbassano, Turin, Italy
| | - A. Ferrari
- University of Bologna, Bologna, Italy; La Sapienza, Rome, Italy; San Luigi Gonzaga Hospital, Orbassano, Turin, Italy
| | - M. Messina
- University of Bologna, Bologna, Italy; La Sapienza, Rome, Italy; San Luigi Gonzaga Hospital, Orbassano, Turin, Italy
| | - D. Cilloni
- University of Bologna, Bologna, Italy; La Sapienza, Rome, Italy; San Luigi Gonzaga Hospital, Orbassano, Turin, Italy
| | - S. Soverini
- University of Bologna, Bologna, Italy; La Sapienza, Rome, Italy; San Luigi Gonzaga Hospital, Orbassano, Turin, Italy
| | - C. Papayannidis
- University of Bologna, Bologna, Italy; La Sapienza, Rome, Italy; San Luigi Gonzaga Hospital, Orbassano, Turin, Italy
| | - M. Baccarani
- University of Bologna, Bologna, Italy; La Sapienza, Rome, Italy; San Luigi Gonzaga Hospital, Orbassano, Turin, Italy
| | - R. Foà
- University of Bologna, Bologna, Italy; La Sapienza, Rome, Italy; San Luigi Gonzaga Hospital, Orbassano, Turin, Italy
| | - G. Martinelli
- University of Bologna, Bologna, Italy; La Sapienza, Rome, Italy; San Luigi Gonzaga Hospital, Orbassano, Turin, Italy
| |
Collapse
|
37
|
Spinello I, Quaranta MT, Pasquini L, Pelosi E, Petrucci E, Pagliuca A, Castelli G, Mariani G, Diverio D, Foà R, Testa U, Labbaye C. PLZF-mediated control on c-kit expression in CD34(+) cells and early erythropoiesis. Oncogene 2009; 28:2276-88. [PMID: 19421145 DOI: 10.1038/onc.2009.87] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The promyelocytic leukemia zinc-finger protein (PLZF) is a transcription factor and c-kit is a receptor tyrosine kinase associated with human disease, particularly in hematopoietic cells. MicroRNAs (miRs) are post-transcriptional regulators of gene expression, and c-kit has been described as a target of miRs-221 and -222 in erythropoiesis. In the present study, we identified c-kit as a target of PLZF in normal and leukemic cells. Particularly, in erythropoietic (E) culture of CD34(+) progenitors, PLZF is downregulated, whereas c-kit expression at both the mRNA and protein levels inversely increases during the first days of E differentiation. In functional experiments, PLZF transfection induces c-kit downregulation, inhibits E proliferation and delays differentiation, whereas PLZF knockdown induces opposite effects, independently of miRs-221 and -222 expression. The inverse correlation between PLZF and c-kit expression was found in normal CD34(+)38(+/-) hematopoietic progenitor/stem cells and in acute myeloid leukemias of M0/M1 French-American-British subtypes, suggesting that the control of PLZF on c-kit expression may be crucial at the level of the stem cell/progenitor compartment. Altogether, our data indicate a new mechanism of regulation of c-kit expression that involves a transcriptional control by PLZF in CD34(+) cells and early erythropoiesis.
Collapse
Affiliation(s)
- I Spinello
- Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Lauria F, Zinzani PL, Raspadori D, Foà R, Buzzi M, Gugliotta L, Bocchia M, Benfenati D, Tura S. Relationship between immunological phenotype and hematological response to alpha-IFN treatment in 35 patients with hairy cell leukemia. Eur J Haematol Suppl 2009; 52:3-6. [PMID: 2279543 DOI: 10.1111/j.1600-0609.1990.tb00895.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
During the past 6 years, clinical trials employing alpha-interferon (alpha-IFN) in hairy cell leukemia (HCL) have shown dramatic improvement in the management of this disease. Complete remissions (CR), however, are relatively rare (10-15%) and a minority of patients (10-25%) do not respond adequately to alpha-IFN. The possibility that the poor response to alpha-IFN treatment could be related to a peculiar immunological phenotype of the hairy cell (HC) was investigated in this study. The results demonstrated that, in the majority of patients who failed to respond to alpha-IFN, HC showed an immunological phenotype characterized by positivity with the CD5 monoclonal antibody which is usually absent on HC and characteristically expressed on B-chronic lymphocytic leukemia cells. In fact, among the 10 HCL patients who presented with this phenotype, only 5 partial remissions (PR) and 5 minor responses (MR) were achieved, as opposed to the 3 complete remissions (CR), 19 PR and 3 MR observed in the 25 CD5-negative patients. The possibility that a more extensive immunological analysis of HCL patients at diagnosis may be predictive of the response to IFN treatment is postulated.
Collapse
Affiliation(s)
- F Lauria
- Istituto di Ematologia e A. Seràgnoli, University of Bologna, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Iacobucci I, Ottaviani E, Astolfi A, Testoni N, Storlazzi T, Papayannidis C, Giannoulia P, Foà R, Baccarani M, Martinelli G. Genome-wide analysis of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients identified recurrent copy number variations in genes regulating the cell cycle and the B-cell differentiation. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.7022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Gorello P, La Starza R, Brandimarte L, Trisolini SM, Pierini V, Crescenzi B, Limongi MZ, Nanni M, Belloni E, Tapinassi C, Gerbino E, Martelli MF, Foà R, Meloni G, Pelicci PG, Mecucci C. A PDGFRB-positive acute myeloid malignancy with a new t(5;12)(q33;p13.3) involving the ERC1 gene. Leukemia 2007; 22:216-8. [PMID: 17690697 DOI: 10.1038/sj.leu.2404894] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
MESH Headings
- Adaptor Proteins, Signal Transducing/genetics
- Adult
- Chromosomes, Human, Pair 12/genetics
- Chromosomes, Human, Pair 5/genetics
- Humans
- In Situ Hybridization, Fluorescence
- Leukemia, Monocytic, Acute/diagnosis
- Leukemia, Monocytic, Acute/genetics
- Leukemia, Monocytic, Acute/therapy
- Male
- Nerve Tissue Proteins/genetics
- Receptor, Platelet-Derived Growth Factor beta/genetics
- Translocation, Genetic
Collapse
|
41
|
Milella M, Ricciardi M, Gregorj C, Abrams S, Steelman L, Chiaretti S, Cognetti F, Foà R, McCubrey J, Tafuri A. 566 POSTER Anti-leukemic activity of the novel MEK inhibitor PD0325901. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)70571-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
42
|
Cartoni C, Brunetti G, Delia G, Foà R. 714 CONTROLLED - RELEASE (CR) OXYCODONE FOR THE TREATMENT OF IATROGENIC NEUROPATHIC PAIN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES. Eur J Pain 2006. [DOI: 10.1016/s1090-3801(06)60717-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
43
|
Quaranta MT, Spinello I, Testa U, Mariani G, Diverio D, Foà R, Peschle C, Labbaye C. PLZF-mediated control on VLA-4 expression in normal and leukemic myeloid cells. Oncogene 2006; 25:399-408. [PMID: 16158049 DOI: 10.1038/sj.onc.1209060] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The promyelocytic leukemia zinc-finger protein (PLZF) is a transcriptional repressor. To investigate the role of PLZF in the regulation of cytoadhesion molecules involved in the mobilization of hemopoietic cells, we have analysed PLZF and very late antigen 4 (VLA-4) expression in normal and leukemic cells. In hematopoiesis, we found a negative correlation between PLZF and VLA-4 expression, except for the megakaryocytic lineage. In contrast, we observed a positive correlation between PLZF and VLA-4 expression in a panel of acute myeloid leukemia (AML) samples. In K562 cells expressing PLZF (K562-PLZF), we found that the expression of VLA-4 and c-kit was downmodulated. We have investigated the possibility for VLA-4 or the c-kit receptor to be direct target genes of PLZF in K562-PLZF cells and identified a PLZF DNA-binding site within the VLA-4 promoter. Furthermore, decrease in VLA-4 expression was associated with loss of adhesion on fibronectin-coated plates, which promotes drug-induced apoptosis of K562-PLZF cells. Our findings indicate that VLA-4 is a potential target gene of PLZF. However, in primary AMLs the control of PLZF on VLA-4 expression is lost. Altogether, we suggest that VLA-4 modulation by PLZF may represent an important step in the control of normal and leukemic cell mobilization.
Collapse
Affiliation(s)
- M T Quaranta
- 1Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Gabriele L, Moretti F, Pierotti MA, Marincola FM, Foà R, Belardelli FM. The use of microarray technologies in clinical oncology. J Transl Med 2006; 4:8. [PMID: 16464241 PMCID: PMC1420332 DOI: 10.1186/1479-5876-4-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2005] [Accepted: 02/07/2006] [Indexed: 12/14/2022] Open
Affiliation(s)
- L Gabriele
- Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy
| | - F Moretti
- Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy
| | - MA Pierotti
- Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
| | - FM Marincola
- Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, USA
| | - R Foà
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, University 'La Sapienza', Rome, Italy
| | - FM Belardelli
- Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy
| |
Collapse
|
45
|
Bizzoni L, Mazzucconi MG, Gentile M, Santoro C, Bernasconi S, Chiarotti F, Foà R, Mandelli F. Idiopathic thrombocytopenic purpura (ITP) in the elderly: clinical course in 178 patients. Eur J Haematol 2006; 76:210-6. [PMID: 16412138 DOI: 10.1111/j.1600-0609.2005.00602.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Idiopathic thrombocytopenic purpura (ITP) is often diagnosed in the elderly (age >or=65 yr), where it generally presents as a chronic disease. The objective of the present study was to describe the natural history of ITP in the elderly and to evaluate the risk of bleeding and the possible occurrence of other pathologies. We retrospectively evaluated 178 ITP patients (82 men, 96 women; mean age: 72 yr) diagnosed between 1981 and 1998. Therapy was started at diagnosis or during follow-up, depending on the platelet count and/or bleeding events. Sixty-six out of one hundred and seventy-eight patients (37%) initiated therapy at diagnosis; whereas in 11 of the 112 untreated patients (9.8%) therapy was necessary during the follow-up. Low-dose of prednisone was the first-line treatment in all patients (mean daily dose of 0.43 mg/kg). Forty-nine (63.6%) of the seventy-seven treated patients showed a response, 14 of these (28.6%) suffered a relapse. Another pathology occurred in 19 of the 178 patients (10.7%). We conclude that low-dose prednisone is an appropriate initial treatment for elderly persons. We also stress that an adequate follow-up is advisable, given that isolated thrombocytopenia could in some cases be the first sign of another underlying pathology.
Collapse
Affiliation(s)
- L Bizzoni
- Divisione di Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Pagano L, Pulsoni A, Vignetti M, Tosti ME, Falcucci P, Fazi P, Fianchi L, Levis A, Bosi A, Angelucci E, Bregni M, Gabbas A, Peta A, Coser P, Ricciuti F, Morselli M, Caira M, Foà R, Amadori S, Mandelli F, Leone G. Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. Ann Oncol 2005; 16:228-33. [PMID: 15668275 DOI: 10.1093/annonc/mdi051] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The aim of the study was to evaluate the outcome of acute myeloid leukaemia (AML) in patients with a previous malignancy (sAML) treated with chemo- and/or radiotherapy, enrolled in conventional trials. PATIENTS AND METHODS In a multicentre setting, a prospective non-concurrent analysis was performed on 2513 new AML patients, aged 12-78 years, consecutively enrolled in EORTC-GIMEMA trials between 1987 and 2001. Thirty-eight patients with sAML were identified and compared with a group of 114 de novo AML patients matched according to age, French-American-British criteria, white blood cell count at diagnosis, trial and time of diagnosis of AML. Induction treatment response, disease-free survival (DFS), duration and overall survival (OS) were evaluated in the two groups. RESULTS Comparing the complete remission (CR) rate between 38 sAML patients and 114 de novo AML patients, selected according to the previously reported criteria, we observed no difference in the CR rates [25/38 (66%) versus 66/114 (58%); Pearson chi(2) 0.7393, P=0.390] as well as no differences while comparing the DFS and the OS between the two groups. CONCLUSION The results of this study suggest that sAML patients are characterised by a good performance status permitting their recruitment in conventional trials without a previous myelodysplastic phase. Similar to de novo AML patients, sAML patients show good response to treatment and the possibility of cure.
Collapse
Affiliation(s)
- L Pagano
- Cattedra di Ematologia, Università Cattolica S. Cuore, Largo Francesco Vito 1, I-00168 Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
La Starza R, Aventin A, Crescenzi B, Gorello P, Specchia G, Cuneo A, Angioni A, Bilhou-Nabera C, Boqué C, Foà R, Uyttebroeck A, Talmant P, Cimino G, Martelli MF, Marynen P, Mecucci C, Hagemeijer A. CIZ gene rearrangements in acute leukemia: report of a diagnostic FISH assay and clinical features of nine patients. Leukemia 2005; 19:1696-9. [PMID: 15990865 DOI: 10.1038/sj.leu.2403842] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
48
|
Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C, Picardi M, Specchia G, Mancini M, Cuneo A, Mecucci C, Martinelli G, Saglio G, Rotoli B, Mandelli F, Salvatore F, Foà R. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia 2005; 19:628-35. [PMID: 15744351 DOI: 10.1038/sj.leu.2403683] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has a dismal prognosis. We prospectively evaluated minimal residual disease (MRD) by measuring BCR/ ABL levels with a quantitative real-time PCR procedure after induction and after consolidation in 45 adults with Ph+ ALL who obtained complete hematological remission after a high-dose daunorubicin induction schedule. At diagnosis, the mean BCR-ABL/GUS ratio was 1.55 +/- 1.78. A total of 42 patients evaluable for outcome analysis were operationally divided into two MRD groups: good molecular responders (GMRs; n = 28) with > 2 log reduction of residual disease after induction and > 3 log reduction after consolidation therapy, and poor molecular responders (PMRs; n = 14) who, despite complete hematological remission, had a higher MRD at both time points. In GMR, the actuarial probability of relapse-free, disease-free and overall survival at two years was 38, 27 and 48%, respectively, as compared to 0, 0 and 0% in PMR (P = 0.0035, 0.0076 and 0.0026, respectively). Salvage therapy induced a second sustained complete hematological remission in three GMR patients, but in no PMR patient. Our data indicate that, as already shown in children, adult Ph+ ALL patients have a heterogeneous sensitivity to treatment, and that early quantification of residual disease is a prognostic parameter in this disease.
Collapse
Affiliation(s)
- F Pane
- CEINGE - Biotecnologie Avanzate and Dipartimento di Biochimica e Biotecnologie Mediche, University 'Federico II di Napolì, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Capello D, Guarini A, Berra E, Mauro FR, Rossi D, Ghia E, Cerri M, Logan J, Foà R, Gaidano G. Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia. Leukemia 2004; 18:1941-7. [PMID: 15483675 DOI: 10.1038/sj.leu.2403537] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Recognition of biased immunoglobulin variable (IgV) gene usage in B-cell chronic lymphocytic leukemia (B-CLL) may yield insight into leukemogenesis and may help to refine prognostic categories. We explored Ig variable heavy (VH) and light (VL) chain gene usage in highly stable and indolent B-CLL (n=25) who never required treatment over 10 or more years. We observed an unexpectedly high usage of mutated VH3-72 (6/25; 24.0%), a gene that was otherwise rare in B-CLL (7/805; 0.87%; P<0.01), including mutated cases (6/432; 1.39%; P<0.01) and was exceptional among indolent (1/230, 0.435%; P<0.01), and aggressive B-cell lymphomas (0/105; P<0.01). Three of six VH3-72 B-CLL cases utilized the same VL Vkappa4-1 gene. Two V(H)3-72 B-CLL cases had highly homologous VH complementarity determining regions 3 (CDR3s), encoding Cys-XXXX-Cys domains, and utilized Vkappa4-1 genes with homologous IgVL CDR3s. An identical threonine to isoleucine change at codon 84 of V(H)3-72 framework region 3 (FR3) recurred in four cases of highly stable VH3-72 B-CLL. This mutation is expected to cause a conformational change of FR3 proximal to CDR3 that might critically affect high-affinity antigen binding. B-cell receptors encoded by VH3-72 may identify a specific B-CLL group and be implicated in leukemogenesis through an antigen-driven expansion of B cells.
Collapse
MESH Headings
- Amino Acid Sequence
- Base Sequence
- Complementarity Determining Regions/chemistry
- Complementarity Determining Regions/genetics
- Gene Rearrangement
- Humans
- Immunoglobulin Heavy Chains/chemistry
- Immunoglobulin Heavy Chains/genetics
- Immunoglobulin Variable Region/chemistry
- Immunoglobulin Variable Region/genetics
- Immunoglobulin kappa-Chains/chemistry
- Immunoglobulin kappa-Chains/genetics
- Immunoglobulin lambda-Chains/chemistry
- Immunoglobulin lambda-Chains/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Molecular Sequence Data
- Mutation
- Prognosis
- Protein Conformation
- Receptors, Antigen, B-Cell/chemistry
- Receptors, Antigen, B-Cell/genetics
- Receptors, Antigen, B-Cell/metabolism
- Sequence Homology, Amino Acid
- Sequence Homology, Nucleic Acid
Collapse
Affiliation(s)
- D Capello
- Hematology Unit, Department of Medical Sciences & IRCAD, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Elia L, Gottardi E, Floriddia G, Grillo R, Ciambelli F, Luciani M, Chiusolo P, Invernizzi R, Meloni G, Foà R, Saglio G, Cimino G. Retrospective comparison of qualitative and quantitative reverse transcriptase polymerase chain reaction in diagnosing and monitoring the ALL1-AF4 fusion transcript in patients with acute lymphoblastic leukaemia. Leukemia 2004; 18:1824-30. [PMID: 15318246 DOI: 10.1038/sj.leu.2403448] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
We compared quantitative reverse transcriptase polymerase chain reaction (Q-RT-PCR) to qualitative RT-PCR in determining response to therapy and predicting clinical outcome in 18 retrospectively selected patients with ALL positive for the ALL1-AF4 fusion and with frozen RNA samples collected at diagnosis and during follow-up (96 samples analysed). The ALL1-AF4 junction was detected by qualitative RT-PCR in 18 patients and by Q-RT-PCR in 17 patients (one patient harboured the rare e10-e6 ALL1-AF4 junction, which falls outside of the primer and probe location designed for the Q-RT-PCR). In three of the 12 patients negative to qualitative RT-PCR after induction therapy, a small number of ALL1-AF4 copies was detected by Q-RT-PCR. Thus nine patients were negative and eight positive. Seven of the eight positive patients suffered a relapse, including two of the three patients positive to Q-RT-PCR yet negative to qualitative RT-PCR. Moreover, we found two (5%) discordant results among the 39 follow-up tests of the nine patients who converted to a negative qualitative-quantitative PCR status. The results suggest that qualitative RT-PCR is more appropriate for the routine diagnosis of this genetic alteration. However, Q-RT-PCR is more accurate in assessing the molecular response after induction treatment and could be more useful in clinical decision-making in ALL1-AF4-positive ALL patients.
Collapse
Affiliation(s)
- L Elia
- Department of Cellular Biotechnology and Haematology, La Sapienza University, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|